RecruitingPhase 3NCT05878860

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Subjects With RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)

Sponsor

Atsena Therapeutics Inc.

Enrollment

97 participants

Start Date

Aug 22, 2023

Study Type

INTERVENTIONAL

Conditions

X-linked Retinoschisis

Summary

This study will evaluate the safety and efficacy of ATSN-201 in subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS).

Eligibility

Min Age: 6 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called ATSN-201 for people with x-linked retinoschisis. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 6 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALATSN-201

AAV.SPR-hGRK1-hRS1syn

Locations(4)

Children's Hospital of Los Angeles

Los Angeles, California, United States

Bascom Palmer Eye Institute

Miami, Florida, United States

Oregon Health Sciences University

Portland, Oregon, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05878860

Related Trials

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

NCT075026641 location

Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)

NCT063458981 location

Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)

NCT058149521 location